SS&C Technologies Holdings Inc. Common Stock vs Zoetis Inc — how do they compare? SS&C Technologies Holdings Inc. Common Stock trades at $82.5 (market cap $19.25B), while Zoetis Inc trades at $76.19 (market cap $31.11B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.82%). Which is the better fit depends on your goals — on Pluang, investors hold SS&C Technologies Holdings Inc. Common Stock for 0 Days and Zoetis Inc for 71 Days on average.
| SSNC | ZTS | |
|---|---|---|
Market Cap | $19.25B | $31.11B |
Volume | 1,341,767 | 2,515,954 |
Sector | Technology | Health |
52-Week High | $89.62 | $147.53 |
52-Week Low | $62.05 | $69.09 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $26.59B | $38.68B |
Dividend Yield | 1.46% | 2.82% |
Signals from Pluang's Aura AI — not financial advice
SSNC trades at $81.52, up 0.65% on the day, with a neutral technical signal. The company has consistently beaten earnings estimates in recent quarters (Q4 2025, Q1 2026, Q2 2026) and shows solid fundamentals, including a 13.16% net income margin and 12.73% ROE. Recent news highlights new client wins and AI-driven product enhancements, reinforcing its market position.
The outlook is positive, supported by strong analyst consensus (70.83% Buy rating) and a $91.50 price target, implying ~12% upside. Key risks include execution of growth initiatives and competitive pressures in the financial technology sector. The stock presents a compelling opportunity for investors seeking a fundamentally sound company with recurring revenue streams.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
SS&C Technologies Holdings, Inc. provides software and outsourced services for financial services and healthcare organizations, covering fund accounting, portfolio management, trading support, and regulatory reporting, and operates as a hedge fund and private equity administrator and mutual fund transfer agent.
Read more on SSNC →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →